12183283.txt 0 development     yeast assay   rapid screening   inhibitors   humanderived pneumocystis carinii dihydrofolate reductase
12183283.txt 1 humanderived pneumocystis carinii dihydrofolate reductase dhfr was expressed     saccharomyces cerevisiae strain whose growth depends   complementation     enzyme   utilized   quantitative assay   measure   sensitivity     yeast strain   dhfr inhibitors   assay should   useful   identifying new inhibitors   humanderived p carinii dhfr
12183283.txt 2 
12183283.txt 3 current treatment   pneumocystis carinii pneumonia pcp   complicated   frequent toxic   allergic side effects emerging drug resistance   limited therapeutic options       clear need   discover new agents against p carinii dihydrofolate reductase dhfr     welldescribed target   antimicrobial chemotherapy   its inhibitors like trimethoprim pyrimethamine   trimetrexate   commonly used drugs   pcp therapy   prophylaxis genes encoding dhfr   p carinii   various mammalian host species have been cloned    amino acid sequence   dhfr   humanderived p carinii differs       ratderived p carinii   38   some     amino acid changes occurring     active sites     enzyme  thus   ideal target   designing potential antifolate drugs     treatment   humans   humanderived p carinii dhfr    expression   recombinant humanderived p carinii dhfr enzyme has permitted kinetic characterization     enzyme   reassessment     inhibitory potency   several commonly used antifolate drugs     vitro enzyme assays    goal     present study was   develop   rapid complementationbased drug screening system   using   yeast saccharomyces cerevisiae expressing humanderived p carinii dhfr   has been previously reported   other organisms    yeast model system used     study was derived   an s cerevisiae strain th5 mataura352 leu23112 trp1 tup1 dfr1ura3 kindly provided   carol hopkins sibley        endogenous dhfr gene   inactivated    humanderived p carinii dhfr coding region was amplified   pcr     plasmid   constructed previously  cloned into an expression vector containing s cerevisiae sequences   permit replication     plasmid   expression     heterologous gene   yeast    transformed into th5 cells     lithium acetate method   transformants were selected   plates containing tryptophandeficient synthetic medium supplemented   100 mug   dtmp sigma st louis mo per ml   plated   rich yeast extractpeptonedextrose medium without dtmp   test   function     construct  th5 yeast strains expressing ratderived p carinii dhfr   human dhfr have been described previously    determine   sensitivity     engineered yeasts   several selected antifolate drugs assays     concentration     drug required   inhibit cell growth   50 ic50 assays were conducted   1 mm sulfanilamide   previously described  each drug was tested   triplicate     least two separate experiments figure    table  illustrate   inhibition patterns   selected dhfr inhibitors   different yeast strains     humanderived p carinii dhfr yeast strain trimethoprim   pyrimethamine were both weak inhibitors   ic50s     micromolar range trimetrexate was about 10fold   40fold   potent than trimethoprim   pyrimethamine respectively wr99210   triazine compound jacobus pharmaceutical company princeton nj has been found     highly effective against malaria dhfr    has   been tested   activity against humanderived p carinii dhfr wr99210 was an even   potent inhibitor   an ic50     108 m range   comparison     ratderived p carinii dhfr strain   humanderived p carinii dhfr strain showed very similar sensitivities   pyrimethamine   wr99210   was about 10fold   sensitive   both trimethoprim   trimetrexate wr99210 exhibited excellent selectivity   both human   ratderived p carinii dhfrs compared       human dhfr while trimethoprim showed   relatively favorable selectivity trimetrexate   pyrimethamine appeared       selective     assay system table  shows   comparison between   ic50s     yeast assay   those   an   vitro enzyme assay based upon previously published data   trimethoprim pyrimethamine   trimetrexate   data generated     study   using previously described methods   conditions wr99210  based   three experiments   mean ic50  standard deviation   wr99210   humanderived p carinii dhfr was 100 10 nm   comparison     relative inhibition profiles     yeast assay   those       vitro assay supports   usefulness     yeast assay   an initial step   identifying new inhibitors   humanderived p carinii dhfr   yeast assay   simple fast   inexpensive   could readily   adapted   automation   usefulness     system   screening   antimicrobial drugs has been well demonstrated   previous studies    ic50 obtained     yeast assay     result     complex function     level   expression     target enzyme     yeast   penetration     drug     cellular location     target enzyme     intrinsic ability     drug   inhibit   enzyme  furthermore   addition   1 mm sulfanilamide     yeast assay   also inhibit   some extent   growth     yeast cells  therefore   actual ic50     yeast assay cannot   compared directly     obtained   an   vitro assay   reflects   direct interaction between   drug     target enzyme under standardized conditions   shown   table    absolute ic50s     four drugs tested showed some differences between   two assay systems     given recombinant strain enzyme expression should   account     relative differences among drugs     yeast assay   those       vitro assay   suggests     abilities     drugs   penetrate   yeast cell wall may differ given   uncertainty about   ability   various drugs   penetrate p carinii compared       yeast application   these observations   potential therapeutic benefit     treatment   pcp must   done cautiously       particular interest     humanderived p carinii dhfr yeast strain showed an approximately 10fold increase   sensitivity   trimetrexate   trimethoprim compared         ratderived p carinii dhfr yeast strain since   host yeast strains   identical differences   penetration should   account     relative differences among drugs demonstrated     yeast assay     vitro assay furthermore given     sensitivities   pyrimethamine   wr99210 were similar     unlikely   these differences represent differential levels   enzyme expression     two yeast strains rather   suggested       vitro enzyme inhibition data   likely reflects   effects     primary sequence differences between human   ratderived p carinii dhfrs  dhfr inhibitors have been among   most studied classes   drugs   treatment   pcp while animal studies  suggest   trimethoprim plays   minimal role     treatment   pcp consistent   its relatively poor inhibition seen       other studies dhfr inhibitors such   trimetrexate clearly have potent antip carinii activity even   single agents    present assay should facilitate identification   additional potent   selective agents
12183283.txt 4 inhibition   dhfr   humanderived p carinii inhibition   dhfr   humanderived p carinii  ratderived p carinii    humans    using s cerevisiae complemented     corresponding dhfr genes   results     representative ic50 assay   shown   each drug tested   yeast growth     control without drug was scored   100     growth   yeast cells   each drug concentration was divided         control   determine   relative growth each point represents   mean value   triplicate data
12183283.txt 5 comparison     ic50s   dhfr inhibitors obtained     yeast complementation assay   those       vitro assay
12183283.txt 6 
